Umbralisib shows early promise for patients with marginal zone lymphoma

Share :
Published: 11 Apr 2019
Views: 1928
Prof Nathan Fowler - MD Anderson Cancer Center, Houston, USA

Prof Nathan Fowler gives a press conference at AACR 2019 on the results from the UNITY-NHL trial which shows that umbralisib is showing activity and is well tolerated in patients with relapsed/refractory marginal zone lymphoma.